Minocycline In Neurocognitive Outcomes - Sickle Cell Disease (MINO-SCD)
Sickle Cell Disease, Cognitive Impairment, Cognitive Decline
About this trial
This is an interventional treatment trial for Sickle Cell Disease focused on measuring sickle cell disease, benign hematology, cognitive dysfunction, neuroinflammation
Eligibility Criteria
Inclusion Criteria: Adults (age ≥ 18 years old) with SCD (HbSS and HbS-β0thalassemia genotypes only) who are followed at the University of Cincinnati Medical Center's SCD clinic are eligible to participate. As hydroxyurea is the standard-of-care in SCD, individuals on hydroxyurea will be included Exclusion Criteria: adults with other SCD genotypes (HbSC or HbS- β+thalassemia), individuals with a history of overt stroke or other known neurological disorder, premature birth before 30 weeks gestation, monthly therapy with chronic blood transfusions, coexisting autoimmune condition due to an elevated risk for autoimmune-related complications with tetracyclines, tetracycline allergy. Women who are pregnant or breast-feeding
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Active Comparator
Placebo Comparator
Treatment arm (1)
Treatment arm (2)
Placebo
This arm will receive 200mg of minocycline in a single capsule per day.
This arm will receive 300 mg of minocycline in a single capsule per day. This capsule is identical in size and appearance as the 200 mg capsule
This arm will receive the placebo which is similar in size and appearance as the 200 mg and 300 mg capsules.